ACT Brief: TrialBlazer Timeline Reductions and Operational Demands, Structural Trial Collaboration and Site Integration, and Henlius-Sandoz Biosimilars Partnership

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part one of a new video interview, Amber Hill, PhD, founder and CEO of Research Grid, explained what hitting the six- to 12-month timeline reductions envisioned under Operation TrialBlazer actually demands operationally. AI-native automation can make the biggest difference earliest when focused on data standardization, site readiness, and early feasibility planning rather than on downstream activities where acceleration is limited by protocol constraints.
• In a new contributed article, Jim Reilly, president of Veeva Development Cloud, argued that faster, higher-quality trials require structural alignment in how sponsors, CROs, and sites plan and execute studies together. Earlier site engagement, shared visibility into study progress, role-based training, and connected technology platforms all work together to shift from fragmented handoffs toward collaborative partnership.
• Henlius Biotech entered a strategic collaboration with Sandoz covering up to 10 monoclonal antibody and antibody-drug conjugate biosimilar products for exclusive ex-China commercialization rights, with total financial consideration up to $322 million. The initial three partnered assets include proposed biosimilars for colorectal cancer, cholesterol management, and systemic lupus erythematosus (uh rith uh mi toe sis), with Sandoz incorporating commercial and market-access input into development and registration strategy from the outset.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.